Clinicopathological, immune and molecular correlates of PD-L2 methylation in gastric adenocarcinomas

Epigenomics. 2019 May;11(6):639-653. doi: 10.2217/epi-2018-0149. Epub 2019 Mar 1.

Abstract

Aim: We investigated the significance of PD-L2 DNA methylation in gastric adenocarcinomas. Methods: We analyzed the methylation at different CpG sites within the PD-L2-encoding gene PDCD1LG2 with regard to correlations and associations with gene expression, clinicopathological parameters, molecular features and immune cell infiltrates in two publicly available cohorts (The Cancer Genome Atlas and Singapore cohorts) of a total of 594 gastric adenocarcinoma patients. Results:PD-L2 methylation is significantly associated with transcriptional activity, survival, Epstein-Barr virus infection, PD-L2 gene amplification, CD8+ T-cell infiltration, microsatellite instability and high mutational load (tumor mutational burden, hypermutation). Conclusion:PD-L2 methylation is associated with known predictive biomarkers of response to anti-PD-1 immunotherapies.

Keywords: , Epstein–Barr virus; DNA methylation; biomarker; gastric cancer; hypermutation; immunotherapy; microsatellite instability.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenocarcinoma / genetics*
  • Adenocarcinoma / immunology
  • Adenocarcinoma / therapy
  • CD8-Positive T-Lymphocytes / physiology
  • CpG Islands
  • DNA Methylation*
  • DNA Mutational Analysis
  • Epstein-Barr Virus Infections / genetics
  • Gene Amplification
  • Gene Expression Regulation, Neoplastic
  • Humans
  • Immunotherapy
  • Microsatellite Instability
  • Programmed Cell Death 1 Ligand 2 Protein / genetics*
  • Stomach Neoplasms / genetics*
  • Stomach Neoplasms / immunology
  • Stomach Neoplasms / therapy
  • Transcription, Genetic

Substances

  • PDCD1LG2 protein, human
  • Programmed Cell Death 1 Ligand 2 Protein